Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Turk J Urol. 2017 Sep;43(3):237-240. doi: 10.5152/tud.2017.01058. Epub 2017 Aug 3.

Score 3 prostate lesions: a gray zone for PI-RADS v2.

Author information

1
Department of Surgical and Biomedical Sciences, Division of Radiology 2, Perugia University, S.Maria Della Misericordia Hospital, S. Andrea Delle Fratte, Perugia, Italy.
2
Division of Urology, University Hospital, Modena, Italy.
3
Department of Experimental Medicine, Magrassi Lanzara, Second University of Naples, Italy.

Abstract

Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) does not offer a precise guidance on the clinical management (biopsy or not biopsy) for PI-RADS v2 score 3 lesions. Lesion volume calculated on biparametric MRI (bpMRI) [T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)] by introducing a cut-off of 0.5 mL, allows to distinguish the lesions assigned by the multiparametric MRI (mpMRI) to the category PI-RADS v2 score 3 in two subgroups: a) Indolent or low risk lesions with volume <0.5 mL, and b) Significant or high risk lesions with volume ≥0.5 mL. For mpMRI lesions assigned to PI-RADS v2 score 3, we suggest the following management: 1) Subgroup a (low-risk lesion): Clinical surveillance (accurate evaluation of age and clinical informations, periodic monitoring of prostate specific antigen value and repeated bpMRI 1 year later); 2) Subgroup b (high-risk lesion): Targeted biopsy. The proposed management would reduce the use of unnecessary biopsies and increase the diagostic yield of significant prostate cancer of approximately 50% and 30% respectively. These approaches encourage the radiologist to adopt MRI lesion volume to improve PI-RADS v2 and to optimize the management of PI-RADS v2 score 3 lesions.

KEYWORDS:

Lesion volume; magnetic resonance imaging; prostate cancer

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center